Lash et al.
catalyst was filtered off, and the solvent was removed under reduced
pressure. The resulting residue was taken up in 3% aqueous
ammonia and neutralized with acetic acid to a litmus end point
while maintaining the temperature of the solution between 0 and
5 °C with the aid of a salt-ice bath. The resulting precipitate was
suction filtered and washed repeatedly with water to remove all
traces of water. After drying overnight in vacuo, the dicarboxylic
acid 24b (1.07 g; 98%) was obtained as a pink powder that was
used without further purification. Tripyrrane 24b (100 mg) was
stirred with TFA (2 mL) in a pear-shaped flask for 10 min under
nitrogen. The solution was diluted with dichloromethane (38 mL),
diformylindene (36 mg) was immediately added, and the solution
stirred in the dark under N2 for an additional 2 h. The solution was
neutralized by the dropwise addition of triethylamine, DDQ (50
mg) was added, and the resulting solution was stirred for an
additional 1 h. The mixure was washed with water, and the solvent
was removed under reduced pressure. The residue was chromato-
graphed on grade 3 alumina eluting with dichloromethane, and the
product was collected as a brown band. Recrystallization from
chloroform-methanol gave the dipropylcarbaporphyrin (57 mg;
52%) as fluffy copper-bronze crystals, mp > 300 °C; UV-vis
(1% Et3N-CHCl3): λmax (log ꢀ) 376 (4.62), 425 (5.23), 511 (4.25),
545 (4.18), 603 (3.80), 662 nm (3.37); UV-vis (0.05% TFA-CHCl3;
monocation): λmax (log ꢀ) 401 (4.75), 439 (5.00), 474 (4.51), 548
(4.09), 586 (3.94), 612 nm (3.93); UV-vis (50% TFA-CHCl3):
mg, 46%) as reddish-purple crystals, mp > 300 °C; UV-vis (1%
Et3N-CHCl3): λmax (log ꢀ) 377 (4.60), 425 (5.17), 511 (4.25), 545
(4.15), 603 (3.80), 663 nm (3.41); UV-vis (0.05% TFA-CHCl3;
monocation): λmax (log ꢀ) 395 (4.41), 440 (4.95), 474 (4.48), 549
(4.08), 588 (3.94), 610 nm (3.93); UV-vis (50% TFA-CHCl3):
1
λmax (log ꢀ) 345 (4.53), 425 (5.17), 614 (3.94), 669 nm (4.37); H
NMR (400 MHz, CDCl3): δ -6.79 (1H, s), -4.08 (2H, br s), 1.27
(12H, d, J ) 6.4 Hz), 1.85 (6H, t, J ) 7.8 Hz), 2.66 (2H, m), 3.56
(6H, s), 3.89-3.97 (8H, m), 7.73-7.77 (2H, m), 8.80-8.83 (2H,
m), 9.75 (2H, s), 10.03 (2H, s);1H NMR (400 MHz, trace TFA-
CDCl3; monocation): δ -6.73 (1H, s), -4.25 (1H, br s), -2.85
(2H, br s), 1.16 (12H, d, J ) 6.8 Hz), 1.87 (6H, t, J ) 7.6 Hz),
2.48 (2H, m), 3.56 (6H, s), 3.91 (4H, d, J ) 7.6 Hz), 4.10 (4H, q,
J ) 7.6 Hz), 7.71-7.74 (2H, m), 8.67-8.70 (2H, m), 10.04 (2H,
s), 10.28 (2H, s);1H NMR (400 MHz, 50% TFA-CDCl3; di-
cation): δ -5.05 (2H, s), -1.33 (3H, br s), 1.28 (12H, d, J ) 6.8
Hz), 1.73 (6H, t, J ) 7.8 Hz), 2.59 (2H, m), 3.58 (6H, s), 3.91
(4H, d, J ) 7.2 Hz), 4.06 (4H, q, J ) 7.6 Hz), 8.95-8.98 (2H, m),
10.13-10.16 (2H, m), 10.49 (2H, s), 11.03 (2H, s);13C NMR
(CDCl3): δ 11.8, 18.7, 20.1, 23.5, 32.3, 35.8, 95.6, 99.1, 109.3,
120.6, 126.6, 131.7, 133.7, 135.5, 136.2, 137.2, 141.4, 144.4, 152.8;
13C NMR (CDCl3, trace TFA-CDCl3; monocation): δ 12.2, 17.8,
19.9, 23.3, 32.1, 35.9, 94.7, 104.9, 119.8, 121.5, 128.1, 134.8, 137.0,
137.4, 138.3, 139.1, 141.1, 141.5, 142.2; 13C NMR (CDCl3, 50%
TFA-CDCl3; dication): δ 12.1, 17.3, 20.2, 22.8, 32.4, 33.1, 35.8,
108.4, 125.0, 134.8, 140.2, 140.6, 142.4, 145.3, 145.9, 146.7, 151.4,
151.7; HRMS (EI): calcd for C39H45N3, 555.3613; found, 555.3619.
Anal. Calcd for C39H45N3.0.6CHCl3: C, 75.81; H, 7.46; N, 6.70.
Found: C, 75.96; H, 7.42; N, 6.71.
1
λmax (log ꢀ) 344 (4.56), 425 (5.24), 615 (3.92), 668 nm (4.42); H
NMR (400 MHz, CDCl3): δ -6.84 (1H, s), -4.07 (2H, br s), 1.29
(6H, t, J ) 7.4 Hz), 1.85 (6H, t, J ) 7.6 Hz), 2.29 (4H, sextet),
3.56 (6H, s), 3.93 (4H, q, J ) 7.6 Hz), 4.01 (4H, t, J ) 7.8 Hz),
7.74-7.77 (2H, m), 8.81-8.84 (2H, m), 9.73 (2H, s), 10.04 (2H,
s);1H NMR (400 MHz, trace TFA-CDCl3; monocation): δ -6.76
(1H, s), -4.52 (1H, br s), -3.09 (2H, br s), 1.19 (6H, t, J ) 7.4
Hz), 1.86 (6H, t, J ) 7.8 Hz), 2.13 (4H, sextet), 3.55 (6H, s), 4.01
(4H, t, J ) 7.4 Hz), 4.10 (4H, q, J ) 7.7 Hz), 7.71-7.74 (2H, m),
8.68-8.71 (2H, m), 10.04 (2H, s), 10.29 (2H, s);1H NMR (400
MHz, 50% TFA-CDCl3; dication): δ -5.06 (2H, s), -1.40 (3H,
br s), 1.34 (6H, t, J ) 7.4 Hz), 1.76 (6H, t, J ) 7.6 Hz), 2.28 (4H,
sextet), 3.60 (6H, s), 4.04 (4H, t, J ) 8 Hz), 4.09 (4H, t, J ) 7.8
Hz), 8.96-9.00 (2H, m), 10.17-10.20 (2H, m), 10.54 (2H, s), 11.10
(2H, s); 13C NMR (CDCl3): δ 11.5, 14.7, 18.7, 20.1, 26.2, 28.6,
95.5, 98.8, 109.4, 120.6, 126.5, 131.2, 133.8, 135.1, 136.3, 137.9,
141.5, 144.4, 152.8; 13C NMR (CDCl3, trace TFA-CDCl3; mono-
cation): δ 11.9, 14.6, 17.7, 19.9, 25.8, 28.7, 94.5, 104.6, 119.6,
121.5, 128.1, 134.5, 137.0, 137.6, 138.4, 140.0, 141.1, 141.2, 142.1;
HRMS (EI): calcd for C37H41N3, 527.3300; found: 527.3292. Anal.
Calcd for C37H41N3‚1/20CHCl3: C, 83.38; H, 7.75; N, 7.87. Found:
C, 83.35; H, 7.76; N, 7.92.
[12,13-Diethyl-7,18-dimethyl-8,17-dipropylbenzo[b]-21-car-
baporphyrinato]silver(III) (15d). A solution of dipropylbenzo-
carbaporphyrin (9d) (12 mg) was reacted with silver(I) acetate under
the conditions used to prepare 9a. Following chromatography on
grade 3 alumina eluting with dichloromethane, the orange product
fraction was recrystallized from chloroform-methanol to give the
silver(III) complex (10.7 mg, 75%) as orange-red crystals, mp >
300 °C; UV-vis (CHCl3): λmax (log ꢀ) 383 (4.42), 437 (4.98), 483
1
(3.71), 518 (3.94), 555 (4.43), 594 nm (3.62); H NMR (CDCl3):
δ 1.33 (6H, t, J ) 7.4 Hz), 1.90 (6H, t, J ) 7.6 Hz), 2.29-2.37
(4H, m), 3.63 (6H, s), 4.00-4.08 (8H, overlapping t and q), 7.79-
7.82 (2H, m), 8.92-8.95 (2H, m), 10.00 (2H, s), 10.22 (2H, s);
HRMS (EI): calcd for C37H38N3Ag, 631.2117; found, 631.2107.
Anal. Calcd for C37H38N3Ag‚1/8CHCl3: C, 68.63; H, 5.93; N, 6.49.
Found: C, 68.61; H, 5.90; N, 6.36.
[12,13-Diethyl-8,17-diisobutyl-7,18-dimethyl-benzo[b]-21-car-
baporphyrinato]silver(III) (15e). The silver complex was prepared
from 9e (12 mg) by the procedure reported above. Recrystallization
from chloroform-methanol gave the silver(III) complex (11.9 mg,
83%) as orange-red crystals, mp > 300 °C; UV-vis (CHCl3):
λmax (log ꢀ) 384 (4.47), 438 (5.03), 483 (3.77), 519 (4.01), 555
(4.49), 594 nm (3.72); 1H NMR (CDCl3): δ 1.30 (12H, d, J ) 6.4
Hz), 1.89 (6H, t, J ) 7.4 Hz), 2.63-2.73 (2H, m), 3.58 (6H, s),
3.89 (4H, d, J ) 7.2 Hz), 4.01 (4H, q, J ) 7.4 Hz), 7.79-7.82
(2H, m), 8.88-8.91 (2H, m), 9.94 (2H, s), 10.13 (2H, s); FD MS:
m/z (rel int) 663.1 (9.8), 662.0 (40), 661.0 (100, M+), 660.0 (43),
659.0 (99, M+). Anal. Calcd for C39H42N3Ag: C, 70.90; H, 6.41;
N, 6.36. Found: C, 70.72; H, 6.11; N, 6.09.
12,13-Diethyl-8,17-diisobutyl-7,18-dimethyl-benzo[b]-21-car-
baporphyrin (9e). Tripyrrane dibenzyl ester (14e) (200 mg) was
hydrogenolysed by the procedure described above to give the
corresponding dicarboxylic acid 10e (145 mg, quantitative) as a
pink powder. Tripyrrane 10e (100 mg) was stirred with TFA (2
mL) in a pear-shaped flask for 2 min under nitrogen, the solution
was diluted with dichloromethane (200 mL), and diformylindene
(33.8 mg) was immediately added. The resulting solution was stirred
in the dark under N2 for an additional 16 h. The mixture was
neutralized by the dropwise addition of triethylamine, DDQ (46
mg) was added, and the resulting solution was stirred for an
additional 30 min. The mixure was washed with water, and the
solvent was removed under reduced pressure. The residue was
chromatographed on grade 3 alumina eluting with dichloromethane,
and the product was collected as a brown band. Recrystallization
from chloroform-methanol gave the diisobutylcarbaporphyrin (50
[5,10,15,20-Tetraphenylbenzo[b]-21-carbaporphyrinato]silver-
(III) (17a). Nitrogen was bubbled through a solution of tetraphen-
ylbenzocarbaporphyrin (16a) (14.8 mg, 0.0223 mmol) in pyridine
(15 mL) for 10 min. Silver acetate (17.4 mg, 0.104 mmol) was
added, and the resulting mixture was stirred under nitrogen for 24
h. The solution was diluted with chloroform, washed with water,
5266 Inorganic Chemistry, Vol. 43, No. 17, 2004